Onco Actu du 9 janvier 2019

	1. BIOLOGIE
Vitamin E's effects on cancer risk may be influenced by genetic variation [UPI] A gene known as catechol-O-methyltransferase, or COMT, is the key to deciding if vitamin E lowers or raises risk of developing cancer, a study published Tuesday in The Journal of the National Cancer Institute.
	3.4 CHIMIOPRÉVENTION
Long-term statin use protects against prostate cancer death [Harvard] Mondul’s investigation showed men who used lipid-lowering drugs for more than 10 years were 33% less likely to develop a fatal prostate cancer and 32% less likely to be diagnosed with prostate cancer in the first place. Moreover, the protective benefits were similarly evident among both white and African American men.
	4.2 DÉP., DIAG. & PRONO. - GÉNOME
23andMe Will Add Weight-Loss Advice to Its DNA-Testing Services [Bloomberg] “The idea is good, but without the proof of peer-reviewed publications with prospective study, we have no knowledge whether these algorithms have any benefit,’’ said Eric Topol, a geneticist at Scripps Research Institute.
	5.12 IMMUNOTHÉRAPIES
Immunotherapy Prompts Shifts in Some Immune Cells Lacking Targeted Checkpoint Proteins [Genome Web] Anderson further noted that the study "helps define an important immune cell population that responds to checkpoint blockade immunotherapy across different cancers and points to a critical factor in this therapy’s success."
	5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
Cellectis CEO Choulika on deals, validation and the future of CAR-T [Fierce Biotech] The future of CAR-T is off the shelf, according to Cellectis CEO André Choulika. Allogeneic CAR-T therapy, which uses donor T cells, has the potential to clear the hurdles that come with autologous CAR-T, which uses a patient’s own T cells.
	5.12.5 IMMUNOTHÉRAPIES - PHARMA
Moderna Announces Recent Progress in Its Immuno-Oncology and Rare Disease Programs and Highlights Corporate Objectives [Moderna] Moderna has 21 mRNA development candidates in its pipeline, with 11 programs now in clinical development.
	5.2.1 PHARMA - PARTENARIATS
MD Anderson Cancer Center and Ascentage Pharma announce strategic alliance in cancer drug development [MD Anderson Cancer Center] MD Anderson’s leukemia team will join in efforts to advance the clinical development of Ascentage’s apoptosis-targeted and tyrosine kinase inhibitor candidates, including Bcr-Abl inhibitor HQP1351, Bcl-2/xL inhibitor APG-1252, Bcl-2 selective inhibitor APG-2575, IAP inhibitor APG-1387 and MDM2-p53 inhibitor APG-115.
Nanobiotix and MD Anderson Cancer Center announce a large-scale, comprehensive clinical collaboration on NBTXR3 [Nanobiotix] The collaboration will expand clinicaldevelopment of NBTXR3, a first-in-class agent designed to physically destroy cancer cells when activated by radiotherapy and to activate the immune system for both local control and systemic disease treatment.
	5.3 TRAITEMENTS - FDA, EMA, NICE...
FDA plans to create a new office to leverage cutting-edge science [STAT] “Eventually the drug review process will look a lot different,” Gottlieb wrote in an email. He envisions a world where data will be uploaded from drug company studies into the cloud, and instead of looking at the charts and tables companies create themselves, the FDA will use its own standardized methods on the raw data.
	5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
FDA's Record Year: A Look at 2018 New Drug Approvals [RAPS] The number of new molecular entities (NMEs) and biologics approved by CDER surpassed the agency's previous record of 53 approvals in 1996 and is a significant jump over the 46 new drugs approved in 2017.
	5.5 ASCO
New Standards for Safe Handling of Hazardous Drugs Focus on Developing Evidence-Based Measures [ASCO] In the new standards, ASCO recommends a comprehensive set of practices and procedures that entities which handle hazardous drugs should incorporate into their occupational safety plan.
	6. LUTTE CONTRE LES CANCERS
What does the NHS Long Term Plan really mean for childhood cancer? [Institute of Cancer Research] It is not yet clear if the NHS has the infrastructure and personnel in place to take on the ambitious target of sequencing the whole genomes of all children with cancer.
	6.1 OBSERVATION
U.S. cancer death rate hits milestone: 25 years of decline [STAT] Lower smoking rates are translating into fewer deaths. Advances in early detection and treatment also are having a positive impact, experts say. But it’s not all good news. Obesity-related cancer deaths are rising, and prostate cancer deaths are no longer dropping.
Cancer Mortality Milestone: 25 years of Continuous Decline [ACS] Racial gap narrowing while socioeconomic inequalities widen.
Cancer Statistics 2019: Cancer Death Rates Have Declined 27% In 25 Years, And We Still Have A Long Way To Go [Dr. Len] Among the good news in this report: A significant decline in death rates from cancer—especially among some of the most common cancers, significant improvements in early detection and treatment of cancer, and a decrease in the disparities in death rates between African-Americans and whites. Despite the good news, unfortunately, there are also pieces of the puzzle that have not been solved.
	6.12 ETHIQUE
How to investigate allegations of research misconduct: A checklist [Retraction Watch] Do investigations into research misconduct allegations need better standards? The Association for the Promotion of Research Integrity (APRIN) in Japan, a group of volunteers who “commit themselves to the promotion of research of high integrity” and provide “e-learning material for research ethics education,” thinks so.
	6.5 MÉDECINES ALTERNATIVES/COMPLÉMENTAIRES
Crowdfunding: The fuel for cancer quackery (part 2) [Science-Based Medicine] In September, The Good Thinking Society released a study estimating the scope of crowdfunding for cancer quackery in the UK. Now, Jeremy Snyder and Tim Caulfield have done the same for the US, specifically for homeopathy for cancer. The results are alarming. Truly, crowdfunding is the fuel for cancer quackery. But will GoFundMe and other crowdfunding sites clean up their acts?